Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled, multicenter study. It is a
13-week Phase 2 study in adults with primary biliary cirrhosis designed to compare the effect
of daily dosing with UDCA in combination with LUM001 or placebo.